SPROHealthcare · BiotechnologyThe 1 Wall Street analysts covering Spero Therapeutics, Inc. hold a median 12-month price target of $4 — +227.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 83 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Spero Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (100): Sales and profits are climbing, and climbing faster than before.
Momentum (18): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SPRO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +227.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | $5.00 |
| 20 Dec 2024 | Evercore ISI Group | Downgrade | In-Line | — |
| 2 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Nov 2024 | TD Cowen | Downgrade | Hold | — |
| 15 Nov 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 4 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 3 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Aug 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 6 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Aug 2024 | TD Cowen | Upgrade | Buy | — |
| 16 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Apr 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 18 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Nov 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Sept 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Aug 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 1 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 July 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Apr 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 Sept 2022 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SPRO appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 61% of US stocks
Cheaper than 60% of US stocks
Cheaper than 54% of US stocks
Cheaper than 56% of US stocks
Higher than 1% of US stocks
Higher than 2% of US stocks
Higher than 71% of US stocks
Higher than 78% of US stocks
Higher than 80% of US stocks
Higher than 86% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Spero Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Spero Therapeutics published the transcript of its Q2 2026 earnings call on Seeking Alpha. The transcript covers the company's second-quarter 2026 financial results and management commentary.
Why it matters — SPRO watchers can review the earnings call transcript for management's detailed discussion of the company's quarterly performance and outlook.
Spero Therapeutics used its second-quarter update to outline a strategic shift toward immune-mediated diseases, supported by the FDA approval of Utebzi and a new licensing agreement for SP001, an antibody candidate planned for initial development in IgG4-related disease.
Why it matters — The update signals a new strategic direction for Spero, with a recent FDA approval and a new licensing deal marking notable near-term developments for the company.
Spero Therapeutics, a clinical-stage biopharmaceutical company focused on immunology and inflammation, announced its financial results for the second quarter ended June 30, 2026, and provided a corporate update. The announcement was made on August 12, 2026.
Why it matters — SPRO watchers would care because the quarterly results and corporate update provide key insights into the company's financial standing and pipeline progress.
Spero Therapeutics announced that on July 22, 2026, its Compensation Committee approved an inducement grant under the 2019 Inducement Equity Incentive Plan to be made on August 3rd to a new employee: an aggregate of 324,622 stock options and 162,311 restricted stock unit awards. The grant is being made under Nasdaq Listing Rule 5635(c)(4).
Why it matters — SPRO watchers would care because this equity inducement grant represents a Nasdaq-rule-governed addition to the company's outstanding option and RSU commitments tied to hiring a new employee.
Spero Therapeutics announced that it will report its financial results for the second quarter ended June 30, 2026, and provide a business update on Wednesday, August 12, 2026, after market close. The announcement was made on August 4, 2026.
Why it matters — SPRO watchers will be able to learn about the company's financial performance and any developments in its immunology and inflammation pipeline when the results and business update are released on August 12.
The 1 Wall Street analysts covering Spero Therapeutics, Inc. have a median 12-month price target of $4, with estimates ranging from $4 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Spero Therapeutics, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Spero Therapeutics, Inc. 83 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Spero Therapeutics, Inc. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (100 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +227.9% from the last close, and Ticker Nerd's factor model ranks Spero Therapeutics, Inc. 83 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Spero Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SPRO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.
Spero Therapeutics, Inc. returned -34.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Spero Therapeutics Inc. is a biopharmaceutical company focused on developing novel treatments for infectious diseases, particularly those caused by antibiotic-resistant bacteria.
The most recent item we track (Seeking Alpha, 13 Aug 2026): "Spero Therapeutics, Inc. (SPRO) Q2 2026 Earnings Call Transcript". Spero Therapeutics published the transcript of its Q2 2026 earnings call on Seeking Alpha. The transcript covers the company's second-quarter 2026 financial results and management commentary.
Spero Therapeutics Inc. is a biopharmaceutical company focused on developing novel treatments for infectious diseases, particularly those caused by antibiotic-resistant bacteria. The primary function of Spero Therapeutics is to address the growing global challenge of bacterial infections that are difficult to treat with existing antibiotics. The company’s pipeline includes innovative therapies targeted at multi-drug resistant bacterial infections, which are essential in hospital and healthcare environments. Spero employs cutting-edge scientific research and development techniques to create oral and intravenous (IV) treatment options that provide effective alternatives for patients and physicians. Headquartered in Cambridge, Massachusetts, Spero Therapeutics plays a critical role in the pharmaceutical industry by advancing the development of new antibiotic therapies, thus contributing to public health and safety. Its work is particularly significant in the context of increasing concerns about antibiotic resistance, which poses a severe threat to global health systems.
CEO Ms. Esther P. Rajavelu · 32 employees · United States · https://sperotherapeutics.com